Jilin Quanyangquan (600189.SH) plans to publicly list and transfer 100% equity of the Park Landscape Company.
Quanyangquan (600189.SH) announced that the company plans to submit application documents to the Jilin Changchun Equity Exchange Center in the near future for the public listing and transfer of its 100% equity in Suzhou Industrial Park Landscape Engineering Co., Ltd. (referred to as "Park Landscape"). The official listing will proceed after approval by the Jilin Changchun Equity Exchange Center.
Jilin Quanyangquan (600189.SH) announced that the company plans to submit application documents to the Jilin Changchun Property Rights Exchange Center in the near future for the public listing and transfer of its 100% equity interest in Suzhou Industrial Park Landscape Engineering Co., Ltd. ("Park Landscape"). The official listing will proceed after approval by the Jilin Changchun Property Rights Exchange Center.
This transaction has been approved by the company's state-owned asset supervisory unit, Jilin Changbai Mountain Tourism Forest Industry Group Co., Ltd., and the state-owned asset evaluation filing procedures with the State-owned Assets Supervision and Administration Commission of Jilin Province for this transaction have been completed. The 100% equity interest in Park Landscape to be publicly listed and transferred is proposed to be split into three portions51%, 30%, and 19%for listing and transfer, with a total minimum listing price of approximately RMB 321 million.
This public listing and transfer of the equity interest in Park Landscape is in line with the company's development strategy, conducive to optimizing the company's asset structure, further focusing on developing its core natural mineral water business, and enhancing the company's overall profitability.
Related Articles

AI infrastructure supplier Accelevation (ACCV.US) races toward U.S. IPO, valued at up to $5.37 billion.

SF INTRA-CITY (09699) repurchased 896,000 shares for HK$7.9905 million on September 22.

Changchun High-Tech Industry (000661.SZ): Clinical trial application for the recombinant human anti-respiratory syncytial virus monoclonal antibody injection combination product has been accepted.
AI infrastructure supplier Accelevation (ACCV.US) races toward U.S. IPO, valued at up to $5.37 billion.

SF INTRA-CITY (09699) repurchased 896,000 shares for HK$7.9905 million on September 22.

Changchun High-Tech Industry (000661.SZ): Clinical trial application for the recombinant human anti-respiratory syncytial virus monoclonal antibody injection combination product has been accepted.






